ELAN
Elanco Animal Health IncPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 6 ▲ Elanco reported Q1 2026 adjusted EPS of $0.40, beating the $0.34 con…
- Jun 29 Clayton Creason v. Elanco US Inc.
- Aug 5 ▲ Elanco reported Q2 2026 adjusted EPS of $0.34, a 26.5% beat vs. the…
- Aug 7 to Aug 20 ▲ 4 days of insider buys: $1.5M by 5 insiders, avg $23.31
- Aug 21 ▲ Elanco Animal Health insiders made $1.03M in net open-market purchas…
- Oct 15 ▼ 1 insider sell $100.0K at $23.00
- Oct 16 Goldman Sachs initiates
- Oct 20 ▼ Jefferies downgrades
- Nov 6 ▲ Earnings: ELAN Q3 2026 Earnings: EPS $0.27 (+30.4% vs est)
- Nov 6 ▲ Elanco reported Q3 2026 revenue of $1.265B (+11% YoY, +9% organic co…
Signal stack
Where each data set points today.
- InsidersBULLISH
5 insiders bought $1.5M at an average $23.31. 1 insider sold $100.0K. Price is 13% above their cost.
- InstitutionsMIXED
Q3 2026: 35 added (1 new), 34 trimmed or exited. Largest new: Qube Research & Technologies $53.0M.
- AnalystsBULLISH
19 of 22 rate it Buy or better. Median target $31.00 (+17%).
- Short sellersSTEADY
Short interest +5.8% to 32.92M shares. 7.2 days to cover, ≈6.6% of shares.
- TrendUPTREND
13% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MARSHALL WACE, LLP | DOUBLED | $224.4M |
| UBS Group AG | TRIM | $117.2M |
| Artemis Investment Management LLP | ADD | $103.3M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | $83.7M |
| Quantinno Capital Management LP | ADD | $73.2M |
| Qube Research & Technologies Ltd | NEW | $53.0M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $43.4M |
| HRT FINANCIAL LP | DOUBLED | $31.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
22 analystsPrice is inside the target range. Median implies +17%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | JP Morgan MAINTAIN | Overweight |
| Oct 29, 2026 | Morgan Stanley MAINTAIN | Equal-Weight |
| Oct 20, 2026 | Jefferies DOWNGRADE | Hold |
| Oct 16, 2026 | Goldman Sachs INITIATE | Buy |
| Aug 6, 2026 | UBS MAINTAIN | Buy |
| Aug 6, 2026 | Keybanc MAINTAIN | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Modi Rajeev A. SEE REMARKS Oct 30, 2026 | AWARD | $1.5K |
VanHimbergen Robert M EVP and CFO Oct 30, 2026 | AWARD | $197.02 |
Simmons Jeffrey N PRESIDENT, CEO AND DIRECTOR Oct 30, 2026 | AWARD | $2.8K |
Modi Rajeev A. SEE REMARKS Oct 16, 2026 | AWARD | $1.5K |
VanHimbergen Robert M EVP and CFO Oct 16, 2026 | AWARD | $197.02 |
Simmons Jeffrey N PRESIDENT, CEO AND DIRECTOR Oct 16, 2026 | AWARD | $2.8K |
Bettington Timothy J SEE REMARKS Oct 15, 2026 | SELL | $100.0K |
Modi Rajeev A. SEE REMARKS Oct 2, 2026 | AWARD | $1.5K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
19 filings · 10 bullish · 0 bearish · 9 neutral- NEUTRAL SC 13G/ANov 16, 2026
T. Rowe Price Investment Management filed an amended Schedule 13G disclosing a 4.5% passive stake in Elanco Animal Health as of September 30, 2026, down from a prior 5.0% stake (implied by the decrease below the 5% threshold). The reduction is modest and consistent with routine portfolio…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 12, 2026
Dodge & Cox filed an amended Schedule 13G disclosing a 12.3% passive stake in Elanco Animal Health…
The reduction is small and typical for a passive manager; no signal of negative conviction. Monitor future 13G filings for further trimming, but this filing alone does not warrant action.
- BULLISH 8-KNov 6, 2026
Elanco reported Q3 2026 revenue of $1.265B (+11% YoY, +9% organic constant currency) and adjusted…
The beat-and-raise quarter with accelerating price, 300 bps gross margin expansion, and leverage milestone below 3.0x signals strong operational momentum. Watch Q4 guidance for 4%-6% organic CC…
- NEUTRAL SC 13G/ANov 5, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G disclosing beneficial ownership of 66,242,260.30…
No prior FMR 13G was provided for comparison, so the direction of stake change is unknown. Monitor for any future 13D conversion or activist activity, though FMR is filing as a passive investor…
All ELAN filing & press-release reports (19)
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 12, 2026
- 8-K reportNov 6, 2026
- SC 13G/A reportNov 5, 2026
- 3 reportNov 3, 2026
- INST-CLUSTER reportOct 14, 2026
- PRESS-RELEASE reportSep 11, 2026
- CLUSTER reportAug 21, 2026
- CLUSTER reportAug 21, 2026
- CLUSTER reportAug 18, 2026
- CLUSTER reportAug 13, 2026
- CLUSTER reportAug 10, 2026
- 8-K reportAug 5, 2026
- COURT-RULING reportJun 29, 2026
- CLUSTER reportMay 19, 2026
- CLUSTER reportMay 19, 2026
- CLUSTER reportMay 19, 2026
- 8-K reportMay 6, 2026
- DEFA14A reportApr 8, 2026